Unknown

Dataset Information

0

Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.


ABSTRACT: BACKGROUND:Trastuzumab has shown a survival benefit in cases of Her2-positive gastroesophageal cancer (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or equivocal results. METHODS:We developed a targeted proteomic assay based on selected reaction monitoring mass spectrometry (SRM-MS) and quantified levels (amol/?g) of Her2-SRM protein in cell lines (n = 27) and GEC tissues (n = 139). We compared Her2-SRM protein expression with IHC/FISH, seeking to determine optimal SRM protein expression cutoffs in order to identify HER2 gene amplification. RESULTS:After demonstrating assay development, precision, and stability, Her2-SRM protein measurement was observed to be highly concordant with the HER2/CEP17 ratio, particularly in a multivariate regression model adjusted for SRM expression of the covariates Met, Egfr, Her3, and HER2 heterogeneity, as well as their interactions (cell lines r (2) = 0.9842; FFPE r (2) = 0.7643). In GEC tissues, Her2-SRM protein was detected at any level in 71.2 % of cases. ROC curves demonstrated that Her2-SRM protein levels have a high specificity (100 %) at an upper-level cutoff of >750 amol/µg and sensitivity of 75 % at a lower-level cutoff of <450 amol/?g for identifying HER2 FISH-amplified tumors. An "equivocal zone" of 450-750 amol/µg of Her2-SRM protein was analogous to IHC2+ but represented fewer cases (9-16 % of cases versus 36-41 %). CONCLUSIONS:Compared to IHC, targeted SRM-Her2 proteomics provided more objective and quantitative Her2 expression with excellent HER2/CEP17 FISH correlation and fewer equivocal cases. Along with its multiplex capability for other relevant oncoproteins, these results demonstrate a refined HER2 protein expression assay for clinical application.

SUBMITTER: Catenacci DVT 

PROVIDER: S-EPMC4871781 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.

Catenacci Daniel V T DVT   Liao Wei-Li WL   Zhao Lei L   Whitcomb Emma E   Henderson Les L   O'Day Emily E   Xu Peng P   Thyparambil Sheeno S   Krizman David D   Bengali Kathleen K   Uzzell Jamar J   Darfler Marlene M   Cecchi Fabiola F   Blackler Adele A   Bang Yung-Jue YJ   Hart John J   Xiao Shu-Yuan SY   Lee Sang Mee SM   Burrows Jon J   Hembrough Todd T  

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20151118 4


<h4>Background</h4>Trastuzumab has shown a survival benefit in cases of Her2-positive gastroesophageal cancer (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or equivocal results.<h4>Methods</h4>We developed a targeted proteomic assay based on selected reaction monitoring mass spectrometry (SRM-MS) and quantified levels (amol/μg) of Her2-SRM  ...[more]

Similar Datasets

| S-EPMC3674507 | biostudies-other
| S-EPMC3013054 | biostudies-literature
| S-EPMC2874747 | biostudies-literature
| S-EPMC2894367 | biostudies-literature
| S-EPMC4802359 | biostudies-literature
| S-EPMC5955866 | biostudies-literature
| S-EPMC6260976 | biostudies-literature